Anthem (NYSE:ANTM – Get Rating) had its price target increased by stock analysts at BMO Capital Markets from $540.00 to $625.00 in a research note issued on Monday, The Fly reports. BMO Capital Markets’ price target would suggest a potential upside of 24.35% from the company’s current price.
A number of other equities analysts have also issued reports on the stock. Sanford C. Bernstein raised their target price on shares of Anthem from $559.00 to $574.00 in a research report on Tuesday, January 11th. Truist Financial raised their target price on shares of Anthem from $590.00 to $610.00 in a research report on Thursday. Wells Fargo & Company set a $586.00 price objective on shares of Anthem and gave the company an “overweight” rating in a research report on Friday. Credit Suisse Group lifted their price objective on shares of Anthem from $518.00 to $584.00 and gave the company an “outperform” rating in a research report on Thursday. Finally, The Goldman Sachs Group lifted their price objective on shares of Anthem from $527.00 to $605.00 and gave the company a “buy” rating in a research report on Thursday. Two research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $543.64.
Shares of ANTM opened at $502.63 on Monday. The stock has a market capitalization of $127.30 billion, a PE ratio of 19.79, a P/E/G ratio of 1.48 and a beta of 1.05. Anthem has a 1 year low of $355.43 and a 1 year high of $533.68. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.47 and a current ratio of 1.36. The company’s 50-day simple moving average is $480.06 and its 200-day simple moving average is $449.50.
In related news, EVP Peter D. Haytaian sold 17,703 shares of the firm’s stock in a transaction dated Thursday, March 10th. The stock was sold at an average price of $460.71, for a total transaction of $8,155,949.13. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Ronald W. Penczek sold 2,423 shares of the firm’s stock in a transaction dated Thursday, March 3rd. The shares were sold at an average price of $463.68, for a total value of $1,123,496.64. The disclosure for this sale can be found here. In the last three months, insiders sold 22,889 shares of company stock valued at $10,532,411. Company insiders own 0.28% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Sound View Wealth Advisors Group LLC lifted its stake in Anthem by 1.9% in the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,267 shares of the company’s stock worth $587,000 after acquiring an additional 24 shares in the last quarter. Allworth Financial LP lifted its stake in Anthem by 35.3% in the 4th quarter. Allworth Financial LP now owns 92 shares of the company’s stock worth $43,000 after acquiring an additional 24 shares in the last quarter. Financial Counselors Inc. lifted its stake in Anthem by 1.3% in the 4th quarter. Financial Counselors Inc. now owns 1,880 shares of the company’s stock worth $871,000 after acquiring an additional 24 shares in the last quarter. PDS Planning Inc lifted its stake in Anthem by 2.9% in the 1st quarter. PDS Planning Inc now owns 850 shares of the company’s stock worth $418,000 after acquiring an additional 24 shares in the last quarter. Finally, Telemus Capital LLC increased its position in Anthem by 1.7% in the 4th quarter. Telemus Capital LLC now owns 1,467 shares of the company’s stock worth $680,000 after purchasing an additional 25 shares during the last quarter. 87.97% of the stock is owned by institutional investors and hedge funds.
About Anthem (Get Rating)
Anthem, Inc, through its subsidiaries, operates as a health benefits company in the United States. It operates through four segments: Commercial & Specialty Business, Government Business, IngenioRx, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small groups, individuals, Medicaid, and Medicare markets.
- Get a free copy of the StockNews.com research report on Anthem (ANTM)
- Time to Buy any Dip in Prologis Stock
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
Receive News & Ratings for Anthem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthem and related companies with MarketBeat.com's FREE daily email newsletter.